T1	intervention 64 73	letrozole
T2	eligibility 508 559	postmenopausal women with early stage breast cancer
T4	ethinicity 703 712	Caucasian
T5	intervention-participants 761 764	352
T6	control-participants 785 789	4708
T7	outcome 860 863	DFS
T8	iv-bin-percent 865 870	91.6%
T9	cv-bin-percent 878 883	92.4%
T16	outcome 1133 1157	incidence of hot flashes
T17	iv-bin-percent 1159 1162	49%
T18	cv-bin-percent 1170 1173	58%
T19	outcome 1186 1193	fatigue
T20	iv-bin-percent 1195 1198	29%
T21	cv-bin-percent 1206 1209	39%
T22	outcome 1227 1236	arthritis
T23	iv-bin-percent 1238 1240	2%
T24	cv-bin-percent 1248 1250	7%
T25	outcome 1304 1314	QOL scores
T12	outcome 1379 1392	mental health
T13	outcome 1439 1450	bodily pain
T14	outcome 1510 1513	DFS
T10	outcome 971 974	DFS
T26	intervention 747 755	Minority
T27	control 770 779	Caucasian
